• Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2020  |  Volume : 6  |  Issue : 1  |  Page : 17-20

Potential inhibitor for 2019-novel coronaviruses in drug development

1 Department of Chemical Drug, Lanzhou Institutes for Food and Drug Control, Lanzhou, Gansu, China
2 Department of Pharmacy, First Hospital of Lanzhou University, Lanzhou, Gansu, China
3 Department of Biliary-Pancreatic Surgery, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
4 Department of Pneumology, First Lanzhou People's Hospital, Lanzhou, Gansu, China
5 Department of Surgery, Gansu People's Hospital, Lanzhou, Gansu, China
6 Department of Medicine, The Fifth People's Hospital of Zhuhai, Zhuhai, Guangdong, China

Correspondence Address:
Prof. Guoyu Qiu
Department of Chemical Drug, Lanzhou Institutes for Food and Drug Control, No. 988, Peng Jia Ping Town, Lanzhou 730050, Gansu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ctm.ctm_3_20

Rights and Permissions

The coronavirus disease 2019 (COVID-19), which is first detected in Wuhan, China, is a virus identified as the cause of pneumonia. In the event of epidemic outbreak, a series of actions have been taken by the Chinese government to control the pandemic of the virus, and effective medical methods are in urgent need to prevent COVID-19 infection and cure the disease, especially a drug that can suppress COVID-19 is urgently needed. However, there are no specific drugs and vaccine that can prevent coronavirus infection. Some research works on the transmissibility, severity, and other features associated with this virus are ongoing. Some works about new drug against COVID-19 are carried out; more time is required to develop an effective drug against pneumonia caused by COVID-19. Now, to develop broad-spectrum antiviral agents, there is a quick method to identify drugs with high binding capacity with COVID-19 by virtual screening based on the clinical drug libraries; all these drugs have been widely used in clinical applications with guaranteed safety, which may serve as promising candidates to treat the infection of COVID-19. In this article, we summarize the discovery and clinical application of specific drugs against COVID-19 as potential inhibitors to alleviate the current epidemic.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded359    
    Comments [Add]    
    Cited by others 2    

Recommend this journal